Ladenburg Thalmann Reiterates Buy Rating on Novavax (NVAX) as Pace of 2019-nCoV Infections Accelerating
Tweet Send to a Friend
Ladenburg Thalmann analyst Michael Higgins reiterated a Buy rating and $27.50 price target on Novavax (NASDAQ: NVAX) with the pace ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
